$NVGN forming a flag (consolidation) $2.37 ht
Post# of 63704
Posted On: 12/27/2014 5:19:08 PM
$NVGN forming a flag (consolidation) $2.37
Website
Shares Outstanding: 6.74M
Float: 5.27M
% Held by Insiders: 4.79%
% Held by Institutions: 0.60%
Shares Short (as of Nov 28, 2014): 104.43K
Short Ratio (as of Nov 28, 2014): 2.80
Short % of Float (as of Nov 28, 2014): N/A
Shares Short (prior month): 96.55K
10/31/14 20-F (Australia)
2014 Annual Report - Full Version >>PDF.
Recent Trades
Headlines
Friday, December 19, 2014
Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85mPR Newswire (Fri, Dec 19)
Wednesday, December 17, 2014
Novogen Raises A$4.1m In Private Placement to US InstitutionsPR Newswire (Wed, Dec 17)
Tuesday, December 16, 2014
Novogen Announces Breakthrough Discovery in the Treatment of MelanomaPR Newswire (Tue, Dec 16)
Novogen Shares Skyrocket 120% Following Drug NewsBenzinga (Tue, Dec 16)
Monday, December 15, 2014
Novogen Provides Update On Progress Of Cantrixil Into The ClinicPR Newswire (Mon, Dec 15)
Monday, September 29, 2014
Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment ConferenceGlobeNewswire (Mon, Sep 29)
ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain CancerPR Newswire (Mon, Sep 29)
Wednesday, September 3, 2014
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare ConferencePR Newswire (Wed, Sep 3)
Wednesday, August 13, 2014
Novogen Announces Results of General Meeting of ShareholdersPR Newswire (Wed, Aug 13)
Tuesday, August 12, 2014
Novogen Receives Funding Support To Commence Studies In Muscular DystrophyPR Newswire (Tue, Aug 12)
Friday, July 25, 2014
Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil™PR Newswire (Fri, Jul 25)
Tuesday, June 17, 2014
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem CellsPR Newswire (Tue, Jun 17)
Thursday, June 5, 2014
5 Reasons Why We Believe Novogen Is Poised For Successat Seeking Alpha (Thu, Jun 5)
Tuesday, May 27, 2014
Novogen rises 14.7%at theflyonthewall.com (Tue, May 27)
Novogen Identifies Highly Active Drug Candidates Against Prostate CancerPR Newswire (Tue, May 27)
Sunday, May 4, 2014
Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood CancersPR Newswire (Sun, May 4)
Friday, May 2, 2014
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative DiseasesPR Newswire (Fri, May 2)
Tuesday, March 18, 2014
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in VivoPR Newswire (Tue, Mar 18)
Wednesday, March 12, 2014
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New YorkPR Newswire (Wed, Mar 12)
Monday, March 10, 2014
Novogen Selected to Present at Cavendish Global Health Impact ForumPR Newswire (Mon, Mar 10)
Website
Shares Outstanding: 6.74M
Float: 5.27M
% Held by Insiders: 4.79%
% Held by Institutions: 0.60%
Shares Short (as of Nov 28, 2014): 104.43K
Short Ratio (as of Nov 28, 2014): 2.80
Short % of Float (as of Nov 28, 2014): N/A
Shares Short (prior month): 96.55K
10/31/14 20-F (Australia)
2014 Annual Report - Full Version >>PDF.
Recent Trades
Headlines
Friday, December 19, 2014
Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85mPR Newswire (Fri, Dec 19)
Wednesday, December 17, 2014
Novogen Raises A$4.1m In Private Placement to US InstitutionsPR Newswire (Wed, Dec 17)
Tuesday, December 16, 2014
Novogen Announces Breakthrough Discovery in the Treatment of MelanomaPR Newswire (Tue, Dec 16)
Novogen Shares Skyrocket 120% Following Drug NewsBenzinga (Tue, Dec 16)
Monday, December 15, 2014
Novogen Provides Update On Progress Of Cantrixil Into The ClinicPR Newswire (Mon, Dec 15)
Monday, September 29, 2014
Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment ConferenceGlobeNewswire (Mon, Sep 29)
ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain CancerPR Newswire (Mon, Sep 29)
Wednesday, September 3, 2014
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare ConferencePR Newswire (Wed, Sep 3)
Wednesday, August 13, 2014
Novogen Announces Results of General Meeting of ShareholdersPR Newswire (Wed, Aug 13)
Tuesday, August 12, 2014
Novogen Receives Funding Support To Commence Studies In Muscular DystrophyPR Newswire (Tue, Aug 12)
Friday, July 25, 2014
Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil™PR Newswire (Fri, Jul 25)
Tuesday, June 17, 2014
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem CellsPR Newswire (Tue, Jun 17)
Thursday, June 5, 2014
5 Reasons Why We Believe Novogen Is Poised For Successat Seeking Alpha (Thu, Jun 5)
Tuesday, May 27, 2014
Novogen rises 14.7%at theflyonthewall.com (Tue, May 27)
Novogen Identifies Highly Active Drug Candidates Against Prostate CancerPR Newswire (Tue, May 27)
Sunday, May 4, 2014
Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood CancersPR Newswire (Sun, May 4)
Friday, May 2, 2014
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative DiseasesPR Newswire (Fri, May 2)
Tuesday, March 18, 2014
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in VivoPR Newswire (Tue, Mar 18)
Wednesday, March 12, 2014
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New YorkPR Newswire (Wed, Mar 12)
Monday, March 10, 2014
Novogen Selected to Present at Cavendish Global Health Impact ForumPR Newswire (Mon, Mar 10)
(0)
(0)Scroll down for more posts ▼